Genetic assessment in primary hyperoxaluria: why it matters
Giorgia Mandrile(University of Turin), Jaap W. Groothoff(University of Amsterdam), Asheeta Gupta(Birmingham Women’s and Children’s NHS Foundation Trust), Cécile Acquaviva(Hospices Civils de Lyon), Lisa J. Deesker(Emma Kinderziekenhuis), Bodo B. Beck(University of Cologne), Sander F. Garrelfs(Emma Kinderziekenhuis), Gill Rumsby(University College London Hospitals NHS Foundation Trust), Justine Bacchetta(Université Claude Bernard Lyon 1)
Cited by 57
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
The primary hyperoxalurias
|Kidney International|2009|373
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling
|Journal of Clinical Investigation|2013|237